{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.970","upperLimit":"1.71","value":"1.45"},{"groupId":"OG001","lowerLimit":"2.11","upperLimit":"4.05","value":"2.81"},{"groupId":"OG002","lowerLimit":"3.70","upperLimit":"5.46","value":"4.54"},{"groupId":"OG003","lowerLimit":"1.69","upperLimit":"8.80","value":"4.40"},{"groupId":"OG004","lowerLimit":"2.11","upperLimit":"6.32","value":"3.51"},{"groupId":"OG005","lowerLimit":"5.75","upperLimit":"18.2","value":"10.5"},{"groupId":"OG006","lowerLimit":"3.87","upperLimit":"14.7","value":"9.29"},{"groupId":"OG007","lowerLimit":"3.65","upperLimit":"16.6","value":"10.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"8"}],"units":"Participants"}],"title":"AMG 224 Conjugated Antibody after Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.811","upperLimit":"1.93","value":"1.51"},{"groupId":"OG001","lowerLimit":"2.44","upperLimit":"4.05","value":"3.06"},{"groupId":"OG002","lowerLimit":"5.97","upperLimit":"7.99","value":"6.71"},{"groupId":"OG003","lowerLimit":"3.33","upperLimit":"10.1","value":"5.91"},{"groupId":"OG004","lowerLimit":"1.91","upperLimit":"12.0","value":"6.64"},{"groupId":"OG005","lowerLimit":"5.75","upperLimit":"20.4","value":"15.2"},{"groupId":"OG006","lowerLimit":"3.87","upperLimit":"36.2","value":"20.0"},{"groupId":"OG007","lowerLimit":"4.68","upperLimit":"27.7","value":"15.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"8"}],"units":"Participants"}],"title":"AMG 224 Conjugated Antibody after Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.05","upperLimit":"2.07","value":"1.70"},{"groupId":"OG001","lowerLimit":"2.56","upperLimit":"5.83","value":"3.91"},{"groupId":"OG002","lowerLimit":"5.52","upperLimit":"8.27","value":"6.69"},{"groupId":"OG003","lowerLimit":"2.78","upperLimit":"9.87","value":"5.50"},{"groupId":"OG004","lowerLimit":"2.86","upperLimit":"8.72","value":"4.86"},{"groupId":"OG005","lowerLimit":"8.14","upperLimit":"17.5","value":"13.5"},{"groupId":"OG006","lowerLimit":"3.47","upperLimit":"18.3","value":"10.9"},{"groupId":"OG007","lowerLimit":"3.76","upperLimit":"15.1","value":"9.47"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"8"}],"units":"Participants"}],"title":"Total Anti-BCMA Antibody after Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.25","upperLimit":"2.78","value":"2.25"},{"groupId":"OG001","lowerLimit":"3.78","upperLimit":"5.83","value":"4.62"},{"groupId":"OG002","lowerLimit":"10.2","upperLimit":"14.7","value":"11.9"},{"groupId":"OG003","lowerLimit":"4.24","upperLimit":"19.1","value":"10.1"},{"groupId":"OG004","lowerLimit":"3.72","upperLimit":"21.0","value":"11.3"},{"groupId":"OG005","lowerLimit":"8.14","upperLimit":"33.6","value":"21.8"},{"groupId":"OG006","lowerLimit":"3.47","upperLimit":"27.4","value":"15.4"},{"groupId":"OG007","lowerLimit":"4.56","upperLimit":"23.7","value":"13.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"8"}],"units":"Participants"}],"title":"Total Anti-BCMA Antibody after Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.00","upperLimit":"0.00","value":"0.00"},{"groupId":"OG001","lowerLimit":"0.00","upperLimit":"0.00","value":"0.00"},{"groupId":"OG002","lowerLimit":"0.00","upperLimit":"0.00","value":"0.00"},{"groupId":"OG003","lowerLimit":"0.00","upperLimit":"0.00","value":"0.00"},{"groupId":"OG004","lowerLimit":"0.00","upperLimit":"0.000341","value":"0.000160"},{"groupId":"OG005","lowerLimit":"0.00","upperLimit":"0.000353","value":"0.000268"},{"groupId":"OG006","lowerLimit":"0.00","upperLimit":"0.000408","value":"0.000206"},{"groupId":"OG007","lowerLimit":"0.00","upperLimit":"0.000694","value":"0.000189"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"10"}],"units":"Participants"}],"title":"DM1 after Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.00","upperLimit":"0.00","value":"0.00"},{"groupId":"OG001","lowerLimit":"0.00","upperLimit":"0.00","value":"0.00"},{"groupId":"OG002","lowerLimit":"0.00","upperLimit":"0.00","value":"0.00"},{"groupId":"OG003","lowerLimit":"0.00","upperLimit":"0.00","value":"0.00"},{"groupId":"OG004","lowerLimit":"0.00","upperLimit":"0.000300","value":"0.000150"},{"groupId":"OG005","lowerLimit":"0.000443","upperLimit":"0.000535","value":"0.000468"},{"groupId":"OG006","lowerLimit":"0.00","upperLimit":"0.000507","value":"0.000254"},{"groupId":"OG007","lowerLimit":"0.000364","upperLimit":"0.000796","value":"0.000494"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"8"}],"units":"Participants"}],"title":"DM1 after Cycle 2"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"10"}],"units":"Participants"}],"description":"Cmin of AMG 224 conjugated antibody, total anti-BCMA antibody and total unconjugated DM1 was measured.","dispersionType":"Full Range","groups":[{"description":"Participants were administered AMG 224 Dose A as an intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG000","title":"Dose Exploration: AMG 224 Dose A"},{"description":"Participants were administered AMG 224 Dose B as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG001","title":"Dose Exploration: AMG 224 Dose B"},{"description":"Participants were administered AMG 224 Dose C as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG002","title":"Dose Exploration: AMG 224 Dose C"},{"description":"Participants were administered AMG 224 Dose D as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG003","title":"Dose Exploration: AMG 224 Dose D"},{"description":"Participants were administered AMG 224 Dose E as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG004","title":"Dose Exploration: AMG 224 Dose E"},{"description":"Participants were administered AMG 224 Dose F as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG005","title":"Dose Exploration: AMG 224 Dose F"},{"description":"Participants were administered AMG 224 Dose G as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG006","title":"Dose Exploration: AMG 224 Dose G"},{"description":"All participants in Dose Expansion who had prior treatment or no prior treatment with a CD38-targeting antibody were administered the MTD of AMG 224 identified in the dose escalation as 3 mg/kg. AMG 224 was administered as an intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG007","title":"Dose Expansion: AMG 224 3 mg/kg"}],"paramType":"MEAN","populationDescription":"The PK parameter analysis set included participants who received at least 1 dose of AMG 224 and for whom PK parameters could be adequately estimated.","reportingStatus":"POSTED","timeFrame":"AMG 224 and anti-BCMA antibody: pre-dose, 0.5 hours, EOI, 4 hours, 24 hours, 96 hours, 168 hours, and 336 hours post-dose (Cycles 1 + 2); DM1: pre-dose, 0.5 hours, EOI, 4 hours, 24 hours, and 96 hours post-dose (Cycles 1 + 2)","title":"Minimum Observed Concentration (Cmin) of AMG 224 Conjugated Antibody, Total Anti-BCMA Antibody, and Total Unconjugated DM1","type":"SECONDARY","unitOfMeasure":"µg/mL"}